KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pfizer (PFE) Equity Average (2016 - 2026)

Pfizer has reported Equity Average over the past 18 years, most recently at $88.3 billion for Q1 2026.

  • Quarterly Equity Average fell 1.43% to $88.3 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $88.3 billion through Mar 2026, down 1.43% year-over-year, with the annual reading at $87.5 billion for FY2025, 3.36% down from the prior year.
  • Equity Average was $88.3 billion for Q1 2026 at Pfizer, down from $89.8 billion in the prior quarter.
  • Over five years, Equity Average peaked at $100.3 billion in Q3 2023 and troughed at $80.1 billion in Q2 2022.
  • The 5-year median for Equity Average is $90.3 billion (2024), against an average of $91.2 billion.
  • Year-over-year, Equity Average surged 69.67% in 2022 and then decreased 9.97% in 2024.
  • A 5-year view of Equity Average shows it stood at $94.4 billion in 2022, then dropped by 1.23% to $93.2 billion in 2023, then decreased by 2.92% to $90.5 billion in 2024, then decreased by 0.82% to $89.8 billion in 2025, then fell by 1.67% to $88.3 billion in 2026.
  • Per Business Quant, the three most recent readings for PFE's Equity Average are $88.3 billion (Q1 2026), $89.8 billion (Q4 2025), and $91.1 billion (Q3 2025).